Alector Inc.
| NASDAQ: ALEC | Healthcare / Biotechnology / USA |
| 17.37 | -2.26 | -11.51% | Vol 972.47K | 1Y Perf -25.79% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 17.33 | ASK | 17.36 | ||
| Open | 19.19 | Previous Close | 19.63 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 33.80 | Analyst Rating | Strong Buy 1.07 | |
| Potential % | 94.59 | Finscreener Ranking | ★★★★ 53.58 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 50.68 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 59.67 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 1.38B | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 32.01 | Earnings Date | 12th May 2021 |
Today's Price Range 17.0719.19 | 52W Range 9.1234.89 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -13.15% | ||
| 1 Month | -0.74% | ||
| 3 Months | 12.79% | ||
| 6 Months | 71.64% | ||
| 1 Year | -25.79% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -139.75 | |||
ROE last 12 Months | -79.34 | |||
ROA (5Y Avg) | -17.35 | |||
ROA last 12 Months | -40.15 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -54.13 | |||
Return on invested Capital Q | -15.46 | |||
Return on invested Capital Y | -67.75 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -8.20 | ||||
| 5.99 | ||||
| 112.86 | ||||
| 10.70 | ||||
| -11.70 | ||||
| -2.14 | ||||
| 5.95 | ||||
| 3.36 | ||||
| 1.23B | ||||
| Forward PE | -7.11 | |||
| PEG | -0.46 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.10 | ||||
| 6.20 | ||||
| 0.14 | ||||
| 0.19 | ||||
| - | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -785.60 | ||||
| -754.20 | ||||
| -1 217.80 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.93M | ||||
| 0.17 | ||||
| 13.76 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.61 | -0.66 | -8.20 |
| Q03 2020 | -0.54 | -0.67 | -24.07 |
| Q02 2020 | -0.52 | -0.58 | -11.54 |
| Q01 2020 | -0.48 | -0.53 | -10.42 |
| Q04 2019 | -0.44 | -0.45 | -2.27 |
| Q03 2019 | -0.42 | -0.47 | -11.90 |
| Q02 2019 | -0.33 | -0.36 | -9.09 |
| Q01 2019 | -0.30 | -0.42 | -40.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.66 | 2.94 | Positive |
| 6/2021 QR | -0.68 | 2.86 | Positive |
| 12/2021 FY | -2.82 | -10.59 | Negative |
| 12/2022 FY | -2.81 | -4.46 | Negative |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.66 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 972.47K |
| Shares Outstanding | 79.58M |
| Trades Count | 13.27K |
| Dollar Volume | 11.30M |
| Avg. Volume | 642.65K |
| Avg. Weekly Volume | 644.75K |
| Avg. Monthly Volume | 843.56K |
| Avg. Quarterly Volume | 658.91K |
Alector Inc. (NASDAQ: ALEC) stock closed at 17.37 per share at the end of the most recent trading day (a -11.51% change compared to the prior day closing price) with a volume of 972.83K shares and market capitalization of 1.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 171 people. Alector Inc. CEO is Arnon Rosenthal.
The one-year performance of Alector Inc. stock is -25.79%, while year-to-date (YTD) performance is 14.81%. ALEC stock has a five-year performance of %. Its 52-week range is between 9.12 and 34.89, which gives ALEC stock a 52-week price range ratio of 32.01%
Alector Inc. currently has a PE ratio of -8.20, a price-to-book (PB) ratio of 5.99, a price-to-sale (PS) ratio of 112.86, a price to cashflow ratio of 10.70, a PEG ratio of 2.32, a ROA of -40.15%, a ROC of -54.13% and a ROE of -79.34%. The company’s profit margin is -%, its EBITDA margin is -754.20%, and its revenue ttm is $13.93 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Alector Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Alector Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Alector Inc. is Strong Buy (1.07), with a target price of $33.8, which is +94.59% compared to the current price. The earnings rating for Alector Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alector Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alector Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.36, ATR14 : 1.42, CCI20 : -23.91, Chaikin Money Flow : -0.03, MACD : -0.26, Money Flow Index : 39.69, ROC : 5.35, RSI : 51.64, STOCH (14,3) : 53.91, STOCH RSI : 1.00, UO : 44.25, Williams %R : -46.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alector Inc. in the last 12-months were: Calvin Yu (Sold 1 343 shares of value $41 981 ), Robert King (Sold 15 000 shares of value $404 958 ), Robert Paul (Option Excercise at a value of $1 124 150), Robert Paul (Sold 174 225 shares of value $3 494 497 )
Alector Inc.
Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain.
CEO: Arnon Rosenthal
Telephone: +1 415 231-5660
Address: 131 Oyster Point Boulevard, South San Francisco 94080, CA, US
Number of employees: 171
